A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Cluster Headache
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 19 Apr 2018
At a glance
- Drugs Galcanezumab (Primary)
- Indications Cluster headache
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly
- 16 Feb 2018 This study has been completed in Spain.
- 31 Jan 2018 This trial has been suspended in Germany.
- 15 Jan 2018 Status changed from recruiting to active, no longer recruiting.